NGL Fine Chem (NGLFINE)

FairStock Score: 33/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I sit with the numbers and ask whether this is a business I understand and a price I can tolerate. NGL Fine Chem operates in pharmaceuticals, with a market cap of ₹1,422 crore and a share price of ₹2,286. The latest quarter shows sales of ₹126 crore and net profit of ₹15 crore. That is encouraging, but one quarter is not a mosaic. Trailing earnings support the current P/E of 47.79, and book value of ₹437.58 gives a P/B of 5.22. These are not Graham-style valuations. A 10.65% ROE and 8.29% ROCE are unimpressive for a company priced like a compounder. The balance sheet is decent—debt/equity is 0.29—and promoter holding at 72.74% aligns owner and management interests. The 45.49% sales growth is real and attractive; the 1,000% profit growth, however, is a low-base optical illusion. A PEG of 0.09 is a mathematical fantasy when the growth rate itself is distorted by a tiny base. Piotroski F-Score of 7/9 tells me recent operations are improving, so there is something real here. But the dividend yield is 0.08%; I am not being paid to wait. The stock has already fallen from a 52-week high of ₹3,602 to ₹2,286, which may look cheaper, but a falling knife is not automatically a bargain. Benjamin Graham said price is what you pay, value is what you get. I cannot find a margin of safety at 47.79 times earnings with a FairStock Score of 30/100 flagged as risky. I would wait for a much lower price or several more quarters of demonstrated earnings power that meaningfully reduces the multiple.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer